Literature DB >> 1687370

Three distinct binding sites for [3H]-prazosin in the rat cerebral cortex.

M Oshita1, S Kigoshi, I Muramatsu.   

Abstract

1. The putative alpha 1-adrenoceptor subtypes of rat cerebral cortex membranes were characterized in binding. 2. Specific binding of [3H]-prazosin was saturable between 20-5000 pm. Scatchard plots of the binding data were non-linear, indicating the presence of two distinct affinity sites for prazosin (pKD, high = 10.18, Rhigh = 308 fmol mg-1 protein; pKD, low = 8.96, Rlow = 221 fmol mg-1 protein). 3. In the membranes pretreated with chlorethylclonidine (CEC) two affinity sites for prazosin were also observed: the affinities were similar to those without CEC pretreatment, but the maximum numbers of binding sites were reduced by CEC pretreatment to 23 and 62% for prazosin-high (Rhigh) and low affinity sites (Rlow), respectively. 4. The prazosin-high affinity sites were further subdivided into two subclasses by WB4101(2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane) and phentolamine; the low affinity sites for WB4101 and phentolamine were more potently inactivated by CEC as compared with the high affinity sites. On the other hand, prazosin, HV723 (alpha-ethyl-3,4,5-trimethoxy-alpha-(3-((2-(2-methoxyphenoxy)ethyl)- amino )-propyl)benzeneacetonitrile fumarate) and yohimbine inhibited [3H]-prazosin binding to prazosin-high affinity sites monophasically. 5. In addition to the high affinity sites, the prazosin-low affinity sites were labelled at high concentrations of [3H]-prazosin. Thus, prazosin and WB4101 showed shallow displacement curves. On the other hand, HV723 and yohimbine did not discriminate between prazosin-high and low affinity sites. 6. Two distinct alpha 1-adrenoceptor subclassifications have been recently proposed (alpha 1A, alpha 1B subtypes and alpha 1H, alpha 1L, alpha 1N subtypes). 5. In both motoneurones and dorsal root fibres, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) effectively depressed the depolarization induced by kainoids, and neither 3-[(+/-)-2-carboxypiperazin-4-yl]propyl-1- phosphonic acid (CPP) nor picrotoxin blocked or affected the depolarization, but there were some differences in pharmacological potencies of glutamate antagonists between both preparations.6. MFPA, HFPA and acromelic acids should provide valuable pharmacological tools for analysis of physiological functions of excitatory amino acids, in particular, as specific agonists for some subtypes of kainate receptors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687370      PMCID: PMC1908822          DOI: 10.1111/j.1476-5381.1991.tb12533.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Alpha 1-adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle.

Authors:  C Han; P W Abel; K P Minneman
Journal:  Nature       Date:  1987 Sep 24-30       Impact factor: 49.962

Review 3.  Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+.

Authors:  K P Minneman
Journal:  Pharmacol Rev       Date:  1988-06       Impact factor: 25.468

4.  Heterogeneity of alpha 1 receptors associated with vascular smooth muscle: evidence from functional and ligand binding studies.

Authors:  M Babich; N W Pedigo; B T Butler; M T Piascik
Journal:  Life Sci       Date:  1987-08-10       Impact factor: 5.037

5.  Different pathways of [3H]inositol phosphate formation mediated by alpha 1a- and alpha 1b-adrenergic receptors.

Authors:  K M Wilson; K P Minneman
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

6.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

7.  Alkylation of alpha-1 receptors with a chemically reactive analog of prazosin reveals low affinity sites for norepinephrine in rabbit aorta.

Authors:  M T Piascik; J W Kusiak; J Pitha; B T Butler; H T Le; M Babich
Journal:  J Pharmacol Exp Ther       Date:  1988-09       Impact factor: 4.030

8.  Evidence for multiple [3H]prazosin binding sites in canine brain membranes.

Authors:  E Mignot; S S Bowersox; J Maddaluno; W Dement; R Ciaranello
Journal:  Brain Res       Date:  1989-05-01       Impact factor: 3.252

9.  Glycogen phosphorylase activation by two different alpha 1-adrenergic receptor subtypes: methoxamine selectively stimulates a putative alpha 1-adrenergic receptor subtype (alpha 1a) that couples with Ca2+ influx.

Authors:  G Tsujimoto; A Tsujimoto; E Suzuki; K Hashimoto
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

10.  Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101.

Authors:  K P Minneman; C Han; P W Abel
Journal:  Mol Pharmacol       Date:  1988-05       Impact factor: 4.436

View more
  19 in total

1.  Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.

Authors:  S Murata; T Taniguchi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Two distinct alpha 1-adrenoceptor subtypes in rabbit liver: a binding study.

Authors:  T Ohmura; I Muramatsu
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

3.  Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor.

Authors:  L Quinton; E Girard; A Maiga; M Rekik; P Lluel; G Masuyer; M Larregola; C Marquer; J Ciolek; T Magnin; R Wagner; J Molgó; R Thai; C Fruchart-Gaillard; G Mourier; J Chamot-Rooke; A Ménez; S Palea; D Servent; N Gilles
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

4.  Analysis of the effects of alpha 1-adrenoceptor antagonists on noradrenaline-mediated contraction of rat small mesenteric artery.

Authors:  P H Van der Graaf; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

5.  Relation between alpha 1-adrenoceptor subtypes and noradrenaline-induced contraction in rat portal vein smooth muscle.

Authors:  I Sayet; G Neuilly; L Rakotoarisoa; C Mironneau; J Mironneau
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

6.  Pharmacological characterization of two distinct alpha 1-adrenoceptor subtypes in rabbit thoracic aorta.

Authors:  M Oshita; S Kigoshi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

7.  Comparison of cloned and pharmacologically defined rat tissue alpha 1-adrenoceptor subtypes.

Authors:  M C Michel; P A Insel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

8.  Pharmacological profiles of a novel alpha 1-adrenoceptor agonist, PNO-49B, at alpha 1-adrenoceptor subtypes.

Authors:  I Muramatsu; T Ohmura; S Kigoshi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-01       Impact factor: 3.000

Review 9.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

10.  Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor.

Authors:  M C Michel; R Büscher; J Kerker; H Kraneis; W Erdbrügger; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.